These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18778179)

  • 1. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
    Riccioni G; Bazzano LA; Bucciarelli T; Mancini B; di Ilio E; D'Orazio N
    Expert Opin Pharmacother; 2008 Oct; 9(14):2403-8. PubMed ID: 18778179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year treatment with rosuvastatin reduces intima-media thickness in 45 hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Vitulano N; Mancini B; Zanasi A; D'Orazio N
    Pharmacology; 2010; 85(2):63-7. PubMed ID: 20110750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin effect on intima media thickness in adult vs elderly patients.
    Riccioni G; Scotti L; Di Ilio E; Bucciarelli V; D'Orazio N; Aceto A; Bucciarelli T
    Front Biosci (Elite Ed); 2012 Jun; 4(7):2618-21. PubMed ID: 22652672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Cipollone F; Santovito D; Scotti L; D'Orazio N; Mezzetti A; Bucciarelli T
    Expert Opin Pharmacother; 2011 Dec; 12(17):2599-604. PubMed ID: 21999752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of intima-media thickness in subjects with asymptomatic carotid disease: two cases from the Asymptomatic Carotid Atherosclerosis DIsease Manfredonia Study (ACADIM Study).
    Riccioni G; D'Orazio N
    Clin Ter; 2007; 158(5):431-3. PubMed ID: 18062350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
    Sawara Y; Takei T; Uchida K; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
    Intern Med; 2008; 47(17):1505-10. PubMed ID: 18758125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein lowering with rosuvastatin in the METEOR study.
    Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
    J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.
    Crouse JR; Grobbee DE; O'Leary DH; Bots ML; Evans GW; Palmer MK; Riley WA; Raichlen JS;
    Cardiovasc Drugs Ther; 2004 May; 18(3):231-8. PubMed ID: 15229392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
    Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
    Circ J; 2012; 76(1):221-9. PubMed ID: 22094911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin: a risk-benefit assessment for intensive lipid lowering.
    Ferdinand KC
    Expert Opin Pharmacother; 2005 Sep; 6(11):1897-910. PubMed ID: 16144509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rosuvastatin in Taiwanese patients.
    Chiang CE; Huang SS; Sung SH
    J Chin Med Assoc; 2008 Mar; 71(3):113-8. PubMed ID: 18364261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.